A 52-year-old man with hypertension is started on atenolol 50 mg daily. After 2 weeks, his blood pressure remains 155/95 mmHg despite good adherence. The physician increases the dose to 100 mg daily. After another 2 weeks, there is minimal further reduction in blood pressure. A repeat dose escalation to 150 mg daily produces no additional benefit. Which pharmacodynamic principle best explains the plateau in blood pressure reduction despite increasing atenolol doses?

Explanation

## Dose-Response Plateau and Receptor Saturation **Key Point:** The plateau in therapeutic response despite dose escalation reflects maximal receptor occupancy — a fundamental principle of pharmacodynamics. Once all available receptors are occupied by the drug, further dose increases cannot produce additional effect. ### The Dose-Response Curve The relationship between drug dose and pharmacological effect follows a sigmoidal (S-shaped) curve: ```mermaid flowchart TD A["Increasing Drug Dose"]:::action --> B{"Receptor Occupancy"}:::decision B -->|"Low dose: Few receptors occupied"| C["Linear response increase"]:::outcome B -->|"Intermediate dose: Proportional occupancy"| D["Steep slope of curve"]:::outcome B -->|"High dose: All receptors saturated"| E["Plateau: No further increase"]:::urgent E --> F["E_max reached (maximal effect)"]:::outcome ``` ### Why the Plateau Occurs 1. **Receptor Saturation**: β-adrenergic receptors in the heart and vasculature are finite in number. At atenolol 100 mg, essentially all receptors are blocked. 2. **E_max Principle**: The maximal effect (E_max) of a drug is determined by the number of receptors available, not the dose. Once E_max is reached, no additional response is possible. 3. **Clinical Correlation**: The patient's blood pressure reduction from baseline (~155/95) to the plateau represents the maximum antihypertensive benefit achievable with β-blockade alone. **High-Yield:** This is **NOT** tachyphylaxis (which involves receptor desensitization over time with continued exposure). Here, the plateau occurs acutely with dose escalation, indicating true receptor saturation. ### Why Other Mechanisms Don't Apply | Mechanism | Why Not Responsible | |-----------|---------------------| | **Receptor desensitization** | Occurs over hours to days; this plateau is immediate with dose increase | | **Competitive antagonism** | Catecholamines cannot overcome a non-competitive antagonist like atenolol at higher doses | | **Increased metabolism** | Atenolol is renally excreted, not hepatically metabolized; metabolism does not increase with dose | **Clinical Pearl:** This patient requires a *different drug class* (e.g., ACE inhibitor, calcium channel blocker) to achieve further blood pressure reduction, not higher atenolol doses. Adding a second agent targets a different physiological pathway. **Mnemonic: E_max = Effect_maximum** — the ceiling of any drug's response, determined by receptor availability and drug-receptor interaction, not dose alone.